14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial-Reference-Cited by-同舟云学术

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial

Published:2012-09 Issue:9846 Volume:380 Page:986-993
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Diacon Andreas H,Dawson Rodney,von Groote-Bidlingmaier Florian,Symons Gregory,Venter Amour,Donald Peter R,van Niekerk Christo,Everitt Daniel,Winter Helen,Becker Piet,Mendel Carl M,Spigelman Melvin K

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. Global tuberculosis control: WHO report,2011

2. Role of individual drugs in the chemotherapy of tuberculosis;Mitchison;Int J Tuberc Lung Dis,2000

3. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis;Rustomjee;Antimicrob Agents Chemother,2008

4. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients;Diacon;Antimicrob Agents Chemother,2010

5. A phase II dose-ranging trial of the early bactericidal activity of PA-824;Diacon;Antimicrob Agents Chemother,2012

Cited by 391 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacology of emerging drugs for the treatment of multi-drug resistant tuberculosis;Journal of Clinical Tuberculosis and Other Mycobacterial Diseases;2024-12

2. A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis;The Lancet Infectious Diseases;2024-09

3. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial;The Lancet Infectious Diseases;2024-09

4. Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles;The Lancet Microbe;2024-09

5. A Narrative Review of Bedaquiline and Delamanid: New Arsenals Against Multidrug‐Resistant and Extensively Drug‐Resistant Mycobacterium tuberculosis;Journal of Clinical Laboratory Analysis;2024-08